Division of Neurological Surgery, Barrow Neurological Institute, St. Joseph's Hospital and Medical Center, Phoenix, Arizona, USA.
World Neurosurg. 2013 Nov;80(5):538-48. doi: 10.1016/j.wneu.2013.02.033. Epub 2013 Feb 9.
Carotid-cavernous fistulas (CCFs) are pathologic arteriovenous shunts between the carotid artery and cavernous sinus. The resulting venous congestion within the cavernous sinus accounts for the classic ocular symptoms associated with these lesions. Endovascular treatment of CCFs has evolved over time to include a variety of transarterial and transvenous embolization techniques. The present series comprises our institutional experience with the endovascular treatment of CCF.
We reviewed our prospectively maintained clinical database for patients with CCF who were evaluated between December 1995 and August 2012. Clinical and demographic data were extracted from medical records, operative notes, and radiographic reports. Cerebral angiograms were reviewed.
The study included 100 (42 direct CCF [dCCF], 58 indirect [iCCF]) patients. Of the 42 patients with dCCF, endovascular treatment was possible in 40 (95%), with an overall 8% morbidity and 2% mortality. Before March 2004, dCCFs were primarily treated with the use of detachable balloons. After the withdrawal of detachable balloons from the market, coil embolization emerged as the first-line treatment. It was accomplished either transarterially or transvenously and often incorporated balloon or stent protection of the parent vessel. After initial treatment, 33 patients (82%) exhibited complete obliteration of their fistula, whereas an additional four (10%) patients demonstrated fistula thrombosis on follow-up angiography. Endovascular access was achieved in 48 (83%) of the 58 patients with iCCF. In this cohort, the morbidity rate was 8%, and there were no deaths. Transvenous approaches were used to treat 88% of these patients and included both transfemoral venous access to the cavernous sinus and direct access through the ophthalmic veins. Immediate fistula occlusion was observed in 37 (77%) patients, and 1 of the 11 patients with a residual fistula progressed to thrombosis on follow-up. Transarterial embolization alone was used in six cases, and five required combined transvenous/transarterial approaches.
For dCCF, the lack of availability of detachable balloons led to the adoption of both transarterial and transvenous coil embolization with adjunctive techniques of parent vessel protection. For iCCF, advances in techniques of venous access have facilitated treatment of lesions with restricted venous outflow. Treatment strategies for CCF continue to evolve with advances in endovascular techniques.
颈动脉海绵窦瘘(CCF)是颈动脉与海绵窦之间病理性动静脉分流。海绵窦内静脉充血导致与这些病变相关的典型眼部症状。CCF 的血管内治疗随时间推移而发展,包括各种经动脉和经静脉栓塞技术。本系列包括我们机构对 CCF 血管内治疗的经验。
我们回顾了 1995 年 12 月至 2012 年 8 月期间接受评估的 CCF 患者的前瞻性维护临床数据库。从病历、手术记录和放射报告中提取临床和人口统计学数据。回顾脑血管造影。
该研究包括 100 例(42 例直接 CCF [dCCF],58 例间接 [iCCF])患者。在 42 例 dCCF 患者中,40 例(95%)可进行血管内治疗,总发病率为 8%,死亡率为 2%。在 2004 年 3 月之前,dCCF 主要采用可分离球囊治疗。可分离球囊撤出市场后,线圈栓塞成为一线治疗方法。它通过经动脉或经静脉进行,并且经常结合球囊或支架保护母血管。初始治疗后,33 例(82%)患者的瘘完全闭塞,另有 4 例(10%)患者在随访血管造影时显示瘘血栓形成。在 58 例 iCCF 患者中,有 48 例(83%)获得了血管内通路。在这一组中,发病率为 8%,无死亡。经静脉途径用于治疗 88%的患者,包括经股静脉进入海绵窦和直接经眼静脉进入。37 例(77%)患者即刻闭塞瘘,11 例残留瘘患者中有 1 例在随访时进展为血栓形成。单独经动脉栓塞用于 6 例,5 例需要联合经静脉/经动脉入路。
对于 dCCF,缺乏可分离球囊导致采用经动脉和经静脉线圈栓塞,并辅以母血管保护技术。对于 iCCF,静脉通路技术的进步促进了治疗静脉流出受限的病变。随着血管内技术的进步,CCF 的治疗策略仍在不断发展。